PE Investors Plug $100M Into NY-Based Cancer Treatment Co.
Lion Biotechnologies Inc., a New York City-based cancer treatment developer, has raised $100 million from a group of investors led by private equity and venture capital firms, the company said on...To view the full article, register now.
Already a subscriber? Click here to view full article